These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 27102950)

  • 1. [Secondary prevention of osteoporotic fractures. How well are we doing?].
    Kyriakos G; Vidal-Casariego A; Quiles-Sánchez LV; Cano-Rodríguez I
    Semergen; 2017 Apr; 43(3):254-255. PubMed ID: 27102950
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical effectiveness of osteoporosis treatment in older patients: A fracture liaison service-based prospective study.
    Mugnier B; Daumas A; Couderc AL; Mizzi B; González T; Amrani A; Lévêque P; Aymes B; Argenson JN; Villani P
    J Women Aging; 2019; 31(6):553-565. PubMed ID: 30295566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement in the rate of inadequate pharmaceutical treatment by orthopaedic surgeons for the prevention of a second fracture over the last 10 years.
    Iba K; Dohke T; Takada J; Sasaki K; Sonoda T; Hanaka M; Miyano S; Yamashita T
    J Orthop Sci; 2018 Jan; 23(1):127-131. PubMed ID: 28982605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Barriers to secondary fracture prevention in primary care.
    Mendis AS; Ganda K; Seibel MJ
    Osteoporos Int; 2017 Oct; 28(10):2913-2919. PubMed ID: 28664275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary prevention program for osteoporotic fractures at Lille University Hospital.
    Abbad N; Lemeunier L; Chantelot C; Puisieux F; Cortet B
    Presse Med; 2016 Mar; 45(3):375-7. PubMed ID: 26826897
    [No Abstract]   [Full Text] [Related]  

  • 6. Impact of the implementation of a Fracture Liaison Service on pharmaceutical expenses for osteoporosis compared to an area without an FLS.
    Naranjo A; Ojeda-Bruno S; Saavedra A; Molina A; Negrín M
    Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):81-87. PubMed ID: 30129375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009.
    Balasubramanian A; Tosi LL; Lane JM; Dirschl DR; Ho PR; O'Malley CD
    J Bone Joint Surg Am; 2014 Apr; 96(7):e52. PubMed ID: 24695929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteoporosis.
    Ensrud KE; Crandall CJ
    Ann Intern Med; 2024 Jan; 177(1):ITC1-ITC16. PubMed ID: 38190715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of osteoporotic refractures in regional Australia.
    Davidson E; Seal A; Doyle Z; Fielding K; McGirr J
    Aust J Rural Health; 2017 Dec; 25(6):362-368. PubMed ID: 28618161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Individualized treatment of osteoporosis].
    Harbeck B; Lehnert H
    Internist (Berl); 2016 Jul; 57(7):638-45. PubMed ID: 27251672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term persistence with anti-osteoporosis drugs after fracture.
    Klop C; Welsing PM; Elders PJ; Overbeek JA; Souverein PC; Burden AM; van Onzenoort HA; Leufkens HG; Bijlsma JW; de Vries F
    Osteoporos Int; 2015 Jun; 26(6):1831-40. PubMed ID: 25822104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary fracture prevention after femur fractures in the Gran Canaria North Health Area: A 2004-2014 comparison.
    Naranjo A; Ojeda-Bruno S; Bilbao Cantarero A; Rodríguez-Moreno S
    Reumatol Clin; 2016; 12(1):58. PubMed ID: 26024587
    [No Abstract]   [Full Text] [Related]  

  • 13. [Application of guidelines for secondary prevention of fracture and the FRAX index in patients with fragility fracture].
    Naranjo A; Ojeda-Bruno S; Francisco-Hernández F; Erausquin C; Rúa-Figueroa I; Rodríguez-Lozano C
    Med Clin (Barc); 2011 Mar; 136(7):290-2. PubMed ID: 21185575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Risk adapted treatment of osteoporosis].
    Pfeilschifter J
    Dtsch Med Wochenschr; 2011 Mar; 136(11):525-32. PubMed ID: 21387211
    [No Abstract]   [Full Text] [Related]  

  • 15. [To where and until when handle the osteoporosis?].
    Uebelhart B; Ferrari S
    Rev Med Suisse; 2017 Apr; 13(559):859-862. PubMed ID: 28727344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonate therapy: how long is long enough?
    McClung MR
    Osteoporos Int; 2015 May; 26(5):1455-7. PubMed ID: 25609156
    [No Abstract]   [Full Text] [Related]  

  • 17. Antiresorptive treatment, when initiated after a first hip fracture, may not protect of a second contralateral episode in elderly population: A study with 685 patients.
    Besalduch M; Carrera I; Gómez-Masdeu M; De Caso J
    Injury; 2016 Apr; 47(4):877-80. PubMed ID: 26892501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Not Available].
    Ferrari S; Lamy O
    Rev Med Suisse; 2017 Apr; 13(559):835-836. PubMed ID: 28727339
    [No Abstract]   [Full Text] [Related]  

  • 19. Fracture risk estimation may facilitate the treatment gap in osteoporosis.
    Lems WF
    Ann Rheum Dis; 2015 Nov; 74(11):1943-5. PubMed ID: 26408569
    [No Abstract]   [Full Text] [Related]  

  • 20. Cancel the denosumab holiday.
    McClung MR
    Osteoporos Int; 2016 May; 27(5):1677-82. PubMed ID: 26932443
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.